Screen LibraryEvaluation of biomarkers and surrogate endpoints in chronic disease
Saved in:
| Corporate Authors: | |
|---|---|
| Group Author: | ; |
| Published: |
National Academies Press,
|
| Publisher Address: | Washington, D.C. |
| Publication Dates: | c2010. |
| Literature type: | Book |
| Language: | English |
| Subjects: | |
| Carrier Form: | xx, 314 p.: ill. ; 23 cm. |
| ISBN: |
9780309151290 (pbk.) 0309151295 (pbk.) 9780309151306 (pdf) 0309151309 (pdf) |
| Index Number: | R44 |
| CLC: | R44 |
| Call Number: | R44/E922 |
| Contents: |
Includes bibliographical references. Review : evaluating and regulating biomarker use -- The biomarker evaluation process -- Case studies-- Strengthening evidence-based regulation. "Many people naturally assume that the claims made for foods and nutritional supplements have the same degree of scientific grounding as those for medication, but that is not always the case. The IOM recommends that the FDA adopt a consistent scientific framework for biomarker evaluation in order to achieve a rigorous and transparent process."--Publisher's description. |